12:00 AM
Nov 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Brilinta ticagrelor: Additional Phase III data

A subgroup analysis of 8,430 ACS patients with ST segment elevation MI (STEMI) in the double-blind, double-dummy, international Phase III PLATO trial showed that 9.4% of patients treated with Brilinta (n=4,201) reached the composite primary endpoint of death from CV death, MI or stroke vs. 11% of patients treated with Plavix clopidogrel (n=4,229) at 12 months (p=0.02). AstraZeneca said the results were driven by a significant...

Read the full 319 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >